| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1214818 | Journal of Chromatography B | 2016 | 6 Pages |
•A sensitive and specific LC–MS/MS method was developed for simultaneous determination of alisol A (A), alisol A 23-acetate (A23) and alisol A 24-acetate (A24) in rat plasma.•In view of the existence of mutual transformation A23 and A24in vivo, simultaneous determination of A23 and A24 is more accurate in rat plasma.•The instability of A23 and A24 in solution have been solved•The LC–MS/MS used in this paper was achieved in 100 μL plasma which was more suitable for small animal pharmacokinetic study due to small blood volume.•We used this method for the pharmacokinetic study of RAE in rat.
We have developed a sensitive and specific LC–MS/MS method for the simultaneous determination of alisol A (A), alisol A 23-acetate (A23) and alisol A 24-acetate (A24), the major active components in Rhizoma Alismatis extract (RAE), in rat plasma. In brief, plasma samples were extracted by methyl tert-butyl ether and chromatographically separated by using a C18 column. A tandem mass spectrometric detection with an electrospray ionization (ESI) interface was conducted via multiple reaction monitoring (MRM) under positive ionization mode. This method was validated for specificity, linearity, accuracy (within ±15.4%), intra- and inter-day precision (CV < 11.4%) over the concentration range of 25–5000 ng/mL for A, and 5–1000 ng/mL for both A23 and A24. The significantly lower detection limit was determined as 25 ng/mL for A, 5 ng/mL for A23 and A24. This validated method of ours was then used to study the pharmacokinetics of RAE in rat. The elimination half-lives (t1/2) of A, A23 and A24 was determined as 0.75, 0.83 and 0.82 h respectively after intravenous injection, and the oral absolute bioavailability of A, A23 and A24 was 43.1 ± 18.1%, 6.3 ± 1.5% and 7.9 ± 1.2%. This new determination method of us for alisols is proven to very useful to study the pharmacological activities of RAE in future.
